

DECLARATION OF INTERESTS

Scientific Committee on Consumer Safety **X**

Health and Environmental Risks

Emerging and Newly Identified Risks

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

*This DoI should be completed in a coherent, clear, comprehensible and detailed manner. It should refer to) **years** before the date of the current declaration. Please do not delete any row, even if not relevant.*

Name: Shareen H. Doak

Position: Member of the Scientific Committee **Consumer Safety**

Working Group... nanomaterials in cosmetics **Full Member**

Ad hoc expert **X**

Title: Professor

Profession: Professor, Swansea University

[please copy rows as needed for subsequent or parallel activities of the same nature]

Nature of Activities	Period	Organisation	Subject matter
----------------------	--------	--------------	----------------

Nature of Activities	Period	Organisation	Subject matter
I. Employment	10/2003 – present	-Swansea University, Wales, UK -Type: public	A research and teaching position in which I currently lead a research group with nanotoxicology being the primary focus. My current research interests are in the health impacts and mechanisms underlying the DNA damaging potential (genotoxicity) of nanomaterials & chemicals, with an emphasis on the use of in vitro screening tests to assess dose-response relationships at low concentrations, necessary for informed health risk assessment.
II. Consultancy/Advisory	MM/YYYY – MM/YYYY	-Name, Place -Type: public, private, ...	Not Relevant

Nature of Activities	Period	Organisation	Subject matter
III. Member of a Managing Body, Scientific Advisory Body or equivalent structure	06/2013 – 06/2017	-UK Committee on Mutagenicity -Type: public (UK Government)	Member of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment. Function of expert: Independent Scientific Expert Advisor Function of body: Independent advisory committee that provides advice to Government departments and agencies on matters concerning the potential mutagenicity of chemicals, from natural products to new synthetic chemicals used in pesticides or pharmaceuticals. Link to website of body: http://www.iacom.org.uk/
IV. Ownership or financial investments, including shares	MM/YYYY – MM/YYYY	Companies or organisations in which the financial interest is placed	Not Relevant
V. Conferences and events (remunerated)	MM/YYYY – MM/YYYY	-Name, Place -Type: public, private,	Not Relevant

Nature of Activities	Period	Organisation	Subject matter
VI. Research grants and other funding	10/2009 – 02/2014	Engineering & Physical Sciences Research Council (public)	Nanoparticle Cytometrics: a quantitative analysis of the toxic effect of nanoparticles
	10/2010 – 10/2014	NC3Rs (public)	The validation of defined genotoxic thresholds, leading to better in vitro risk assessments of carcinogenic potential
	04/2012 – 01/2015	NC3Rs (public)	Developing an integrated “in vitro carcinogenicity predictive tool” utilising in vitro cell signalling and objective cell phenotype data coupled with in vitro genotoxicity data
	10/2012 – 10/2015	Engineering & Physical Sciences Research Council (public)	Defining nanomaterial characteristics that influence inflammatory and genotoxic impact using airway models
	04/2013 – 04/2014	Royal Mint (Government owned company)	Characterising the toxic propensity of microparticles on human cells
	10/2013 – 10/2016	AstraZeneca / Medical Research Council (private / public respectively)	Mechanisms underlying genotoxic thresholds: the development of automated tools for mechanistic investigations in vitro
	10/2013 – 10/2016	Tenovus (charity fund)	The role of STEAP2 in prostate cancer invasion and metastasis
VII. Intellectual property	MM/YYYY – MM/YYYY		Not Relevant

Nature of Activities	Period	Organisation	Subject matter
VIII. Other membership or affiliation or any other relevant interests	2003 – present	UK Environment & Mutagen Society	www.ukems.org.uk
	2009 – present	British Toxicological Society	www.thebts.org
	2007 – present	Institute of Nanotechnology	www.nano.org.uk
	2009 – present	British Association of Cancer Research	www.bacr.org.uk
	2013 - present	ILSI/HESI Genetic Toxicology Technical Committee (GTTC) International Nanomaterials Steering Team (within the New Compounds Workgroup)	http://www.hesiglobal.org/i4a/pages/

Nature of Activities	Period	Organisation	Subject matter
IX. Principal investigator or investigator	10/2009 – 02/2014	Engineering & Physical Sciences Research Council (public)	Co-PI: Nanoparticle Cytometrics: a quantitative analysis of the toxic effect of nanoparticles
	10/2010 – 10/2014	NC3Rs (public)	Co-I: The validation of defined genotoxic thresholds, leading to better in vitro risk assessments of carcinogenic potential
	04/2012 – 01/2015	NC3Rs (public)	Co-I: Developing an integrated “in vitro carcinogenicity predictive tool” utilising in vitro cell signalling and objective cell phenotype data coupled with in vitro genotoxicity data
	10/2012 – 10/2015	Engineering & Physical Sciences Research Council (public)	PI: Defining nanomaterial characteristics that influence inflammatory and genotoxic impact using airway models
	04/2013 – 04/2014	Royal Mint (Government owned company)	PI: Characterising the toxic propensity of microparticles on human cells
	10/2013 – 10/2016	AstraZeneca / Medical Research Council (private / public respectively)	Co-I: Mechanisms underlying genotoxic thresholds: the development of automated tools for mechanistic investigations in vitro
	10/2013 – 10/2016	Tenovus (charity fund)	PI: The role of STEAP2 in prostate cancer invasion and metastasis
X. Interests of immediate family members	MM/YYYY – MM/YYYY	-Name, Place -Type: public, private,	Not Relevant

I hereby declare on my honour that I have read the guidance for completing this form, the Guidelines of Scientific Committees' guidelines on the assessing of declarations of interests and the Rules and Procedure related to Independence (section V of the Rules of Procedure) and that I agree to the conditions included therein. I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DOI form including the changes.

Done at ...9.2.15.....Date:

Signature 
